SOR102
Ulcerative Colitis / Inflammatory Bowel Disease (IBD)
Phase 1bActive
Key Facts
Indication
Ulcerative Colitis / Inflammatory Bowel Disease (IBD)
Phase
Phase 1b
Status
Active
Company
About Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, USA. The company is pioneering a platform for orally delivered single-domain antibodies ('Vorabodies') aimed at treating autoimmune and inflammatory diseases, with a lead program in ulcerative colitis. Recent positive Phase 1b data for SOR102 and a publication in The Lancet Gastroenterology & Hepatology validate its innovative approach. Sorriso's technology promises targeted, local therapy with manufacturing and stability advantages over traditional injectable antibodies.
View full company profile